SLC7A11 and metabolic dysfunction-associated steatotic liver disease: In addition, it was demonstrated that ECH slows down the progression of MASLD by regulating mitochondrial function and inhibiting ferroptosis through the Nrf2/SLC7A11/GPX4 signaling pathway.